These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 16158059

  • 1. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain.
    Reichman C, Singh K, Liu Y, Singh S, Li H, Fajardo JE, Fiser A, Birge RB.
    Oncogene; 2005 Dec 08; 24(55):8187-99. PubMed ID: 16158059
    [Abstract] [Full Text] [Related]

  • 2. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.
    Zvara A, Fajardo JE, Escalante M, Cotton G, Muir T, Kirsch KH, Birge RB.
    Oncogene; 2001 Feb 22; 20(8):951-61. PubMed ID: 11314030
    [Abstract] [Full Text] [Related]

  • 3. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
    Brasher BB, Roumiantsev S, Van Etten RA.
    Oncogene; 2001 Nov 22; 20(53):7744-52. PubMed ID: 11753652
    [Abstract] [Full Text] [Related]

  • 4. Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.
    Jung JH, Pendergast AM, Zipfel PA, Traugh JA.
    Biochemistry; 2008 Jan 22; 47(3):1094-104. PubMed ID: 18161990
    [Abstract] [Full Text] [Related]

  • 5. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
    Pisabarro MT, Serrano L, Wilmanns M.
    J Mol Biol; 1998 Aug 21; 281(3):513-21. PubMed ID: 9698566
    [Abstract] [Full Text] [Related]

  • 6. An intramolecular SH3-domain interaction regulates c-Abl activity.
    Barilá D, Superti-Furga G.
    Nat Genet; 1998 Mar 21; 18(3):280-2. PubMed ID: 9500553
    [Abstract] [Full Text] [Related]

  • 7. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.
    Van Etten RA, Debnath J, Zhou H, Casasnovas JM.
    Oncogene; 1995 May 18; 10(10):1977-88. PubMed ID: 7539119
    [Abstract] [Full Text] [Related]

  • 8. The C-terminal SH3 domain of the mouse c-Crk protein negatively regulates tyrosine-phosphorylation of Crk associated p130 in rat 3Y1 cells.
    Ogawa S, Toyoshima H, Kozutsumi H, Hagiwara K, Sakai R, Tanaka T, Hirano N, Mano H, Yazaki Y, Hirai H.
    Oncogene; 1994 Jun 18; 9(6):1669-78. PubMed ID: 8183562
    [Abstract] [Full Text] [Related]

  • 9. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
    Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, Kuriyan J.
    Mol Cell; 2006 Mar 17; 21(6):787-98. PubMed ID: 16543148
    [Abstract] [Full Text] [Related]

  • 10. Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation.
    Sriram G, Reichman C, Tunceroglu A, Kaushal N, Saleh T, Machida K, Mayer B, Ge Q, Li J, Hornbeck P, Kalodimos CG, Birge RB.
    Oncogene; 2011 Nov 17; 30(46):4645-55. PubMed ID: 21602891
    [Abstract] [Full Text] [Related]

  • 11. CrkIII: a novel and biologically distinct member of the Crk family of adaptor proteins.
    Prosser S, Sorokina E, Pratt P, Sorokin A.
    Oncogene; 2003 Jul 31; 22(31):4799-806. PubMed ID: 12894221
    [Abstract] [Full Text] [Related]

  • 12. Examining the specificity of Src homology 3 domain--ligand interactions with alkaline phosphatase fusion proteins.
    Yamabhai M, Kay BK.
    Anal Biochem; 1997 Apr 05; 247(1):143-51. PubMed ID: 9126384
    [Abstract] [Full Text] [Related]

  • 13. Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide.
    Donaldson LW, Gish G, Pawson T, Kay LE, Forman-Kay JD.
    Proc Natl Acad Sci U S A; 2002 Oct 29; 99(22):14053-8. PubMed ID: 12384576
    [Abstract] [Full Text] [Related]

  • 14. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.
    Polverini E, Rangaraj G, Libich DS, Boggs JM, Harauz G.
    Biochemistry; 2008 Jan 08; 47(1):267-82. PubMed ID: 18067320
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the proline-rich region of mouse MAPKAP kinase 2: influence on catalytic properties and binding to the c-abl SH3 domain in vitro.
    Plath K, Engel K, Schwedersky G, Gaestel M.
    Biochem Biophys Res Commun; 1994 Sep 15; 203(2):1188-94. PubMed ID: 8093038
    [Abstract] [Full Text] [Related]

  • 16. Critical amino acid substitutions in the Src SH3 domain that convert c-Src to be oncogenic.
    Miyazaki K, Senga T, Matsuda S, Tanaka M, Machida K, Takenouchi Y, Nimura Y, Hamaguchi M.
    Biochem Biophys Res Commun; 1999 Oct 05; 263(3):759-64. PubMed ID: 10512753
    [Abstract] [Full Text] [Related]

  • 17. Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain.
    Pisabarro MT, Serrano L.
    Biochemistry; 1996 Aug 20; 35(33):10634-40. PubMed ID: 8718852
    [Abstract] [Full Text] [Related]

  • 18. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
    Groysman M, Nagano M, Shaanan B, Katzav S.
    Oncogene; 1998 Sep 24; 17(12):1597-606. PubMed ID: 9794237
    [Abstract] [Full Text] [Related]

  • 19. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
    Mysliwiec T, Perego R, Kruh GD.
    Oncogene; 1996 Feb 01; 12(3):631-40. PubMed ID: 8637720
    [Abstract] [Full Text] [Related]

  • 20. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites.
    Ren R, Ye ZS, Baltimore D.
    Genes Dev; 1994 Apr 01; 8(7):783-95. PubMed ID: 7926767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.